440 related articles for article (PubMed ID: 25380934)
1. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
2. GDF15 is related to anemia and hepcidin in kidney allograft recipients.
Malyszko J; Koc-Zorawska E; Malyszko JS; Glowinska I; Mysliwiec M; Macdougall IC
Nephron Clin Pract; 2013; 123(1-2):112-7. PubMed ID: 23797049
[TBL] [Abstract][Full Text] [Related]
3. Hemojuvelin and iron metabolism in kidney and heart allograft recipients.
Przybylowski P; Koc-Zorawska E; Glowinska I; Levin-Iaina N; Macdougall IC; Malyszko JS; Mysliwiec M; Malyszko J
Transplant Proc; 2013; 45(1):391-3. PubMed ID: 23375327
[TBL] [Abstract][Full Text] [Related]
4. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
[No Abstract] [Full Text] [Related]
5. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
6. A possible role of hepcidin in the pathogenesis of anemia in heart allograft recipients.
Przybylowski P; Malyszko J; Malyszko JS
Transplant Proc; 2010 Jun; 42(5):1803-7. PubMed ID: 20620527
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.
Fertrin KY; Lanaro C; Franco-Penteado CF; de Albuquerque DM; de Mello MR; Pallis FR; Bezerra MA; Hatzlhofer BL; Olbina G; Saad ST; da Silva Araújo A; Westerman M; Costa FF
Am J Hematol; 2014 Apr; 89(4):385-90. PubMed ID: 24860871
[TBL] [Abstract][Full Text] [Related]
8. Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment.
Hong JH; Choi YK; Min BK; Park KS; Seong K; Lee IK; Kim JG
Diabetes Res Clin Pract; 2015 Jul; 109(1):64-70. PubMed ID: 25998917
[TBL] [Abstract][Full Text] [Related]
9. Iron metabolism, hepcidin, and anemia in orthotopic heart transplantation recipients treated with mammalian target of rapamycin.
Przybylowski P; Malyszko JS; Macdougall IC; Malyszko J
Transplant Proc; 2013; 45(1):387-90. PubMed ID: 23375326
[TBL] [Abstract][Full Text] [Related]
10. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transplant Proc; 2009 Oct; 41(8):3056-9. PubMed ID: 19857675
[TBL] [Abstract][Full Text] [Related]
11. Iron Status in Newly Diagnosed
Susanah S; Rakhmilla LE; Ghozali M; Trisaputra JO; Moestopo O; Sribudiani Y; Idjradinata PS; Maskoen AM
Biomed Res Int; 2021; 2021():5560319. PubMed ID: 33954177
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis.
Huang Y; Liu R; Wei X; Liu J; Pan L; Yang G; Lai Y
Biomed Res Int; 2019; 2019():4504302. PubMed ID: 30834265
[TBL] [Abstract][Full Text] [Related]
13. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia.
Theurl I; Finkenstedt A; Schroll A; Nairz M; Sonnweber T; Bellmann-Weiler R; Theurl M; Seifert M; Wroblewski VJ; Murphy AT; Witcher D; Zoller H; Weiss G
Br J Haematol; 2010 Feb; 148(3):449-55. PubMed ID: 19863534
[TBL] [Abstract][Full Text] [Related]
14. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I.
Tamary H; Shalev H; Perez-Avraham G; Zoldan M; Levi I; Swinkels DW; Tanno T; Miller JL
Blood; 2008 Dec; 112(13):5241-4. PubMed ID: 18824595
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Am J Hematol; 2006 Nov; 81(11):832-7. PubMed ID: 16929540
[TBL] [Abstract][Full Text] [Related]
16. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841
[TBL] [Abstract][Full Text] [Related]
17. Absolute and Functional Iron Deficiency Is a Common Finding in Patients With Heart Failure and After Heart Transplantation.
Przybylowski P; Wasilewski G; Golabek K; Bachorzewska-Gajewska H; Dobrzycki S; Koc-Zorawska E; Malyszko J
Transplant Proc; 2016; 48(1):173-6. PubMed ID: 26915864
[TBL] [Abstract][Full Text] [Related]
18. Elevated Hepcidin Is Part of a Complex Relation That Links Mortality with Iron Homeostasis and Anemia in Men and Women with HIV Infection.
Minchella PA; Armitage AE; Darboe B; Jallow MW; Drakesmith H; Jaye A; Prentice AM; McDermid JM
J Nutr; 2015 Jun; 145(6):1194-201. PubMed ID: 25904736
[TBL] [Abstract][Full Text] [Related]
19. Anemia in heart and kidney allograft recipients: is there a role for hepcidin?
Przybylowski P; Malyszko J; Malyszko JS; Koc-Zorawska E; Sadowski J; Mysliwiec M
Transplant Proc; 2010 Dec; 42(10):4255-8. PubMed ID: 21168677
[TBL] [Abstract][Full Text] [Related]
20. Soluble TNFα receptor type I and hepcidin as determinants of development of anemia in the long-term follow-up of heart failure patients.
Martínez-Ruiz A; Tornel-Osorio PL; Sánchez-Más J; Pérez-Fornieles J; Vílchez JA; Martínez-Hernández P; Pascual-Figal DA
Clin Biochem; 2012 Nov; 45(16-17):1455-8. PubMed ID: 22609894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
